IR & Research Intelligence, Sessa Investment Research

Sessa Investment Research

IR & Research Intelligence

Sponsored research focusing on Japanese small cap.

Equity Bottom-Up

D.Western Therapeutics Institute Inc. / Equity Bottom-Up

D.Western Therapeutics Institute Inc. (4576 JP)

<ul>
<li>D. Western Therapeutics Institute, Inc. (DWTI, hereafter the Company) announced its H1 FY2026/12 results after market close on August 13, 2026.</li>
<li>For TissueBlue , the Company and licensee DORC are currently discussing detailed terms and conditions for extending their agreement in the US, where the patent remains in force.</li>
<li>SIR believes that if the planned product launches proceed on schedule, expectations for the Company will rise further and be reflected in its share price.</li>
</ul>


D. Western Therapeutics Institute, Inc. (DWTI, hereafter the Company) announced its H1 FY2026/12 results after market close on August 13, 2026.
For TissueBlue , the Company and licensee DORC are currently discussing detailed terms and conditions for extending their agreement in the US, where the patent remains in force.
SIR believes that if the planned product launches proceed on schedule, expectations for the Company will rise further and be reflected in its share price.


D. Western Therapeutics Institute | 4576 FY2026/12 Q2 Follow-Up

Japan

MEDRx Co Ltd., is a pharmaceutical company. The Company develops medicines for the pharmaceutical industry based on drug formulation technologies required for Drug Delivery Systems.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Medrx Co Ltd (4586 JP)

D. Western Therapeutics Institute | 4576 FY2026/12 Q2 Follow-Up

D. Western Therapeutics Institute, Inc. (DWTI, hereafter the Company) announced its H1 FY2026/12 results after market close on August 13,...

Sessa Investment Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)